By Fineline Cube 
Belgium-based biopharmaceutical company UCB (EBR: UCB) announced plans to invest in a cutting-edge biologics production facility in the United States. This strategic move aims to meet the growing demand from its U.S. patient population and is expected to generate an estimated USD 5 billion in economic impact.
Economic and Employment Impact
The project is anticipated to create approximately 300 permanent positions and over 500 construction jobs. It underscores UCB’s commitment to expanding its U.S. operations and supporting its growth-driven product portfolio and future R&D initiatives.
Site Selection Process
Comprehensive feasibility studies are currently underway to identify the optimal location for the facility. Key considerations include the availability of a skilled workforce and access to robust innovation ecosystems.-Fineline Info & Tech